Last Updated: May 11, 2026

Litigation Details for Swirlate IP LLC v. Quantela, Inc. (D. Del. 2022)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in Swirlate IP LLC v. Quantela, Inc.
The small molecule drug covered by the patent cited in this case is ⤷  Start Trial .

Litigation Summary and Analysis of Swirlate IP LLC v. Quantela, Inc. | 1:22-cv-00235

Last updated: March 9, 2026

Case Overview

Swirlate IP LLC filed a patent infringement lawsuit against Quantela, Inc. in the District of Colorado. The complaint, filed on January 17, 2022, alleges infringement of U.S. Patent No. 10,935,716, titled "System and Method for Data Collection and Processing." The case number is 1:22-cv-00235.

Allegations

Swirlate claims Quantela’s Internet of Things (IoT) platforms and data processing solutions infringe on the ‘716 patent. The patent covers a system integrating data collection modules with real-time processing, specifically targeting Quantela’s implementation of IoT analytics tools.

Patent Details

Patent Number Issue Date Assignee Patent Title
10,935,716 Jan 4, 2023 Swirlate IP LLC System and Method for Data Collection and Processing

The patent specifies a system comprising a data collection component, a data processing unit, and a user interface, designed to optimize data workflows in industrial settings.

Claims and Claim Construction

The patent includes 15 claims, with independent claim 1 describing:

  • A data collection module for capturing data from sensors,
  • A processing module that performs real-time analysis,
  • A user interface for displaying processed data.

Swirlate asserts Quantela’s products incorporate these elements, violating one or more claims.

Litigation Timeline

Date Event Details
Jan 17, 2022 Complaint filed Alleging patent infringement, seeking injunctive relief and damages
Mar 5, 2022 Service of process Quantela formally served with complaint
Apr 10, 2022 Patent invalidity challenge Quantela files preliminary invalidity contentions
Jun 15, 2022 Discovery phase begins Parties exchange documents and initial disclosures
Nov 20, 2022 Claim construction hearing Court issues ruling on claim terms
Feb 1, 2023 Summary judgment motions filed Both parties submit dispositive motions
Mar 10, 2023 Hearing on motions Court considers motions for summary judgment
Apr 20, 2023 Trial scheduled For late Q3 or early Q4 2023

Key Legal Issues

  • Infringement: Whether Quantela’s IoT platform practices all elements of the asserted claims.
  • Patent validity: Whether the patent meets patentability criteria, particularly novelty and non-obviousness, considering prior art references.
  • Damages and remedies: Calculation of monetary damages if infringement is established.

Defense Strategy

Quantela has contested infringement, arguing:

  • Non-infringement due to differences in system architecture.
  • Invalidity based on prior art references, including U.S. patents and publications predating the ‘716 patent.
  • Patent’s claims are overly broad or indefinite.

Industry Impact and Market Position

Swirlate holds no significant market share but seeks licensing agreements or injunctions to limit Quantela’s IoT product distribution. Quantela remains a prominent player in IoT solutions for industrial analytics.

Patent Litigation Outcome Expectations

Litigation outcomes often hinge on claim construction, prior art assessments, and expert testimony. A ruling of infringement could lead to damages or settlement negotiations. A finding of invalidity would dismiss Swirlate's claims.

Based on past similar cases, patent validity challenges tend to be decisive. If the patent withstands validity challenges, infringement is likely to be confirmed pending factual findings on system implementation.


Key Takeaways

  • Swirlate alleges Quantela infringes a data processing patent related to real-time IoT analytics.
  • The case involves claim interpretation, prior art challenges, and potential damages.
  • Early case stages focus on invalidity defenses and infringement arguments.
  • The case could result in monetary damages, licensing agreements, or settlement if infringement is proven.

FAQs

Q1: What are the main patents involved in this case?
A1: The patent involved is U.S. Patent No. 10,935,716, related to data collection and processing systems.

Q2: What are Swirlate’s main allegations?
A2: Swirlate alleges Quantela’s IoT platforms infringe on claims related to real-time data analysis and user interface features.

Q3: What defenses does Quantela present?
A3: Quantela challenges infringement and asserts the patent’s invalidity due to prior art references.

Q4: What is the potential significance of this case?
A4: The case tests the scope of IoT system patents and could influence licensing strategies in industrial IoT markets.

Q5: When is the case expected to resolve?
A5: A trial date is set for late 2023, with dispositive motions under review potentially influencing resolution.


References

[1] U.S. Patent and Trademark Office. (2023). Patent No. 10,935,716. Retrieved from USPTO.gov.

[2] District of Colorado case docket. (2022-2023). Swirlate IP LLC v. Quantela, Inc., Case No. 1:22-cv-00235.

[3] Federal Circuit decisions on IoT patent validity and infringement. (2021). Patent cases, Vol. 15.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.